TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07033026: An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Sponsor: NGM Biopharmaceuticals, Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 136 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07033026 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07033026 Rescue Dossier →